Loading...
Please wait, while we are loading the content...
Similar Documents
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
| Content Provider | Scilit |
|---|---|
| Author | Moccia, Alden A. Taverna, Christian Schär, Sämi Vanazzi, Anna Rondeau, Stéphanie Hitz, Felicitas Mingrone, Walter Pabst, Thomas Cevreska, Lidija Giglio, Auro Del Raats, Johann Rauch, Daniel Vorobiof, Daniel A. Lohri, Andreas Ruegsegger, Céline Rudolf, Christine Biaggi Rusterholz, Corinne Hayoz, Stefanie Ghielmini, Michele Zucca, Emanuele |
| Copyright Year | 2020 |
| Description | The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03 randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules in patients with follicular lymphoma (FL). Here, we report their long-term treatment outcome. Two-hundred and seventy FL patients were treated with 4 weekly doses of rituximab monotherapy (375 mg/m2); 165 of them, achieving at least a partial response, were randomly assigned to maintenance rituximab (375 mg/m2 every 2 months) on a short-term (4 administrations; n = 82) or a long-term (up to a maximum of 5 years; n = 83) schedule. The primary end point was event-free survival (EFS). At a median follow-up period of 10 years, median EFS was 3.4 years (95% confidence interval [CI], 2.1-5.5) in the short-term arm and 5.3 years (95% CI, 3.5-7.5) in the long-term arm. Using the prespecified log-rank test, this difference is not statistically significant (P = .39). There also was not a statistically significant difference in progression-free survival or overall survival (OS). Median OS was 11.0 years (95% CI, 11.0-NA) in the short-term arm and was not reached in the long-term arm (P = .80). The incidence of second cancers was similar in the 2 arms (9 patients after short-term maintenance and 10 patients after long-term maintenance). No major late toxicities emerged. No significant benefit of prolonged maintenance became evident with longer follow-up. Notably, in symptomatic patients in need of immediate treatment, the 10-year OS rate was 83% (95% CI, 73-89%). These findings indicate that single-agent rituximab may be a valid first-line option for symptomatic patients with advanced FL. |
| Related Links | https://ashpublications.org/bloodadvances/article-pdf/4/23/5951/1793619/advancesadv2020002858.pdf |
| Ending Page | 5957 |
| Page Count | 7 |
| Starting Page | 5951 |
| DOI | 10.1182/bloodadvances.2020002858 |
| Journal | Blood advances |
| Issue Number | 23 |
| Volume Number | 4 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-12-08 |
| Access Restriction | Open |
| Subject Keyword | Hematology Treatment Survival Rituximab Maintenance Prolonged Term Arm Sakk Journal: Blood advances (Vol- 136, Issue- 23) |
| Content Type | Text |
| Resource Type | Article |
